MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Mycophenolate (Cellcept®)

Selected References

  • Abdulaziz HM, et al. 2021. Fetal proximal and distal limb anomalies following exposure to mycophenolate mofetil during pregnancy: A case report and review of the literature. Lupus 30(9):1522-1525.
  • Alsebayel MM, et al. 2018. Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofeil exposure during pregnancy: A case report and review of the literature. Am J Case Rep 3(19):523-526.
  • Boyle S, et al. 2021.Pregnancy following heart transplantation: A single centre case series and review of the literature. Heart Lung Circ 30:144–53.
  • Coscia LA, et al. 2015. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 4(2):42-55.
  • Egeberg A, et al 2017 Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception-A Danish population-based cohort study. J Invest Dermatol. 137(8):1790-1792.
  • Hoeltzenbein M, et al. 2012. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A(3):588-596.
  • Huerta A, et al. 2021. Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis. Kidney Int 100(3):711.
  • Intas Pharmaceuticals. Last updated Jan. 5, 2024. Mycophenolate mofetil drug label information. Available at URL: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741e079a-646b-47ec-84ac-8e12574c2aaf
  • Jones A, et al. 2013. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. Prog Transplant 23(2):153-157.
  • Khan F, et al. 2022. Fetal malformations associated with exposure to mycophenolic acid during the first trimester. Int J Pediatr Adolesc Med 9(3):171-173.
  • Kim M, et al. 2013. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 13(6):1383-1389.
  • King RW, et al. 2017. Pregnancy outcomes related to mycophenolate exposure in female kidney transplant recipients. Am J Transplant 17(1):151-160.
  • Krutsch K, et al. 2023. Transfer of mycophenolic acid into human milk. J Nephrol 36:1715-7.
  • Martin MC, et al. 2014. Esophageal atresia and prenatal exposure to mycophenolate. Reprod Toxicol 50:117-121.
  • Martin- Moreno PL, et al. 2021. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. Clin Transplant 35(5):e14256.
  • Midtvedt K, et al. 2017. Exposure to mycophenolate and fatherhood. Transplantation 101(7);e214-217.
  • Perez-Aytes A, et al. 2017. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16-21.
  • Sifontis NM, et al. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.